DE122005000011I1 - Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen. - Google Patents
Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.Info
- Publication number
- DE122005000011I1 DE122005000011I1 DE200512000011 DE122005000011C DE122005000011I1 DE 122005000011 I1 DE122005000011 I1 DE 122005000011I1 DE 200512000011 DE200512000011 DE 200512000011 DE 122005000011 C DE122005000011 C DE 122005000011C DE 122005000011 I1 DE122005000011 I1 DE 122005000011I1
- Authority
- DE
- Germany
- Prior art keywords
- hyperactivity
- tomoxet
- treatment
- attention deficit
- deficit disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/371,341 US5658590A (en) | 1995-01-11 | 1995-01-11 | Treatment of attention-deficit/hyperactivity disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
DE122005000011I1 true DE122005000011I1 (de) | 2005-06-23 |
DE122005000011I2 DE122005000011I2 (de) | 2006-02-09 |
Family
ID=23463572
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200512000011 Active DE122005000011I2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen |
DE69623141T Expired - Lifetime DE69623141T2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69623141T Expired - Lifetime DE69623141T2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen |
Country Status (28)
Country | Link |
---|---|
US (1) | US5658590A (de) |
EP (1) | EP0721777B1 (de) |
JP (2) | JPH10512262A (de) |
KR (1) | KR19980701276A (de) |
CN (2) | CN1168095A (de) |
AT (1) | ATE222757T1 (de) |
AU (1) | AU688665B2 (de) |
BR (1) | BR9606903A (de) |
CA (1) | CA2209735C (de) |
CZ (1) | CZ292226B6 (de) |
DE (2) | DE122005000011I2 (de) |
DK (1) | DK0721777T3 (de) |
ES (1) | ES2181845T3 (de) |
FI (1) | FI119354B (de) |
FR (1) | FR10C0041I2 (de) |
HU (1) | HU227306B1 (de) |
LU (1) | LU91238I2 (de) |
NL (1) | NL300180I2 (de) |
NO (1) | NO317027B1 (de) |
NZ (1) | NZ301500A (de) |
PL (1) | PL187573B1 (de) |
PT (1) | PT721777E (de) |
RO (1) | RO118374B1 (de) |
RU (1) | RU2163802C2 (de) |
SI (1) | SI0721777T1 (de) |
TR (1) | TR199700627T1 (de) |
UA (1) | UA43385C2 (de) |
WO (1) | WO1996021430A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
GB9613243D0 (en) * | 1996-06-25 | 1996-08-28 | Britannia Pharmaceuticals Ltd | Attention deficit hyperactive disorder |
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
WO1999015177A1 (en) * | 1997-09-23 | 1999-04-01 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
KR20010034758A (ko) * | 1998-04-09 | 2001-04-25 | 로렌스 티. 마이젠헬더 | 신경 장애의 신규 치료 방법 |
US6586427B2 (en) | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
WO2000027428A1 (en) * | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6898455B2 (en) * | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
US6400978B1 (en) | 1999-10-29 | 2002-06-04 | The Mclean Hospital Corporation | Method and apparatus for detecting mental disorders |
PL357042A1 (en) * | 2000-03-07 | 2004-07-12 | Eli Lilly And Company | Treatment of psoriasis |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
CN1713900A (zh) * | 2001-12-11 | 2005-12-28 | 伊莱利利公司 | 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 |
GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
WO2004017977A2 (en) | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
US20060100290A1 (en) * | 2003-07-28 | 2006-05-11 | Dunaway Leslie J | Treatment of allergic rhinitis and asthma |
EP1660064A2 (de) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Behandlung von lernstörungen und motorischen störungen mit norepinephrin-wiederaufnahme-hemmern |
CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
CA2552064A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
BRPI0511529A (pt) * | 2004-05-27 | 2008-01-02 | Warner Lambert Co | combinação terapêutica para distúrbios de hiperatividade/déficit de atenção |
US7507861B2 (en) * | 2004-06-28 | 2009-03-24 | Teva Pharmaceutical Fine Chemicals, S.R.L. | Process for the preparation of atomoxetine hydrochloride |
US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
CA2568629A1 (en) * | 2004-07-22 | 2006-02-23 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetine hydrochloride |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US7569729B2 (en) * | 2005-04-05 | 2009-08-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
AU2006318476A1 (en) * | 2005-11-23 | 2007-05-31 | Auspex Pharmaceuticals, Inc. | Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
EP1963268B1 (de) | 2005-12-07 | 2010-12-01 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Disubstituierte phenylpiperidine als modulatoren der corticalen catecholaminergen neurotransmission |
US20080020387A1 (en) * | 2006-03-31 | 2008-01-24 | Lawrence Donald G | Biomarker-optimized adhd treatment |
US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US20080031932A1 (en) * | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
US20080145318A1 (en) * | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
EP2341912B1 (de) | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Verfahren zur behandlung oder abschwächung von aufmerksamkeitsdefizit/hyperaktivitätsstörungen (adhs) |
RU2395313C2 (ru) * | 2008-10-15 | 2010-07-27 | Татьяна Прохоровна Тетерина | Способ коррекции синдрома дефицита внимания и гиперактивности |
JP5309262B2 (ja) | 2009-12-02 | 2013-10-09 | アプタリス ファーマ リミテッド | フェキソフェナジン・マイクロカプセル及びそれを含む組成物 |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
WO2012129551A1 (en) | 2011-03-23 | 2012-09-27 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP4233915A3 (de) | 2012-02-08 | 2023-09-20 | Supernus Pharmaceuticals, Inc. | Modifizierte freisetzungsformulierungen von viloxazin |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
CN105705135A (zh) | 2013-11-08 | 2016-06-22 | 伊莱利利公司 | 阿托莫西汀溶液 |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457121A (en) * | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
-
1995
- 1995-01-11 US US08/371,341 patent/US5658590A/en not_active Expired - Lifetime
-
1996
- 1996-01-04 CZ CZ19972145A patent/CZ292226B6/cs not_active IP Right Cessation
- 1996-01-04 RU RU97113060/14A patent/RU2163802C2/ru active
- 1996-01-04 CN CN96191412A patent/CN1168095A/zh active Pending
- 1996-01-04 RO RO97-01260A patent/RO118374B1/ro unknown
- 1996-01-04 CA CA002209735A patent/CA2209735C/en not_active Expired - Lifetime
- 1996-01-04 CN CNA2005100832846A patent/CN1781480A/zh active Pending
- 1996-01-04 TR TR97/00627T patent/TR199700627T1/xx unknown
- 1996-01-04 BR BR9606903A patent/BR9606903A/pt unknown
- 1996-01-04 HU HU9801283A patent/HU227306B1/hu active Protection Beyond IP Right Term
- 1996-01-04 NZ NZ301500A patent/NZ301500A/en not_active IP Right Cessation
- 1996-01-04 KR KR1019970704665A patent/KR19980701276A/ko not_active Application Discontinuation
- 1996-01-04 WO PCT/US1996/000091 patent/WO1996021430A1/en not_active Application Discontinuation
- 1996-01-04 AU AU46938/96A patent/AU688665B2/en not_active Expired
- 1996-01-04 PL PL96321273A patent/PL187573B1/pl unknown
- 1996-01-04 JP JP8521732A patent/JPH10512262A/ja not_active Withdrawn
- 1996-01-09 SI SI9630534T patent/SI0721777T1/xx unknown
- 1996-01-09 ES ES96300157T patent/ES2181845T3/es not_active Expired - Lifetime
- 1996-01-09 EP EP96300157A patent/EP0721777B1/de not_active Expired - Lifetime
- 1996-01-09 AT AT96300157T patent/ATE222757T1/de active
- 1996-01-09 DK DK96300157T patent/DK0721777T3/da active
- 1996-01-09 DE DE200512000011 patent/DE122005000011I2/de active Active
- 1996-01-09 DE DE69623141T patent/DE69623141T2/de not_active Expired - Lifetime
- 1996-01-09 PT PT96300157T patent/PT721777E/pt unknown
- 1996-04-01 UA UA97073620A patent/UA43385C2/uk unknown
-
1997
- 1997-07-08 NO NO19973170A patent/NO317027B1/no not_active IP Right Cessation
- 1997-07-09 FI FI972922A patent/FI119354B/fi not_active IP Right Cessation
-
2005
- 2005-03-04 NL NL300180C patent/NL300180I2/nl unknown
- 2005-08-10 JP JP2005232408A patent/JP2005325139A/ja active Pending
-
2006
- 2006-05-03 LU LU91238C patent/LU91238I2/fr unknown
-
2010
- 2010-08-20 FR FR10C0041C patent/FR10C0041I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE122005000011I1 (de) | Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen. | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69435330D1 (de) | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen | |
BR0010600A (pt) | Método para inativação de cisto de giardia e cryptosporidium usando-se luz ultravioleta | |
RU97113060A (ru) | Лечение синдрома дефицита внимания/гиперактивности | |
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
NZ313076A (en) | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders | |
DE59202663D1 (de) | Verwendung eines UV-Strahlers zur Behandlung von Oberflächen. | |
DE3884895D1 (de) | Verwendung von Bezafibrat zur Behandlung von Diabetes. | |
DE69720064D1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
ATE354361T1 (de) | Neue verwendung von prodigiosin zur behandlung von diabetes mellitus | |
DE69711422D1 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina | |
ATE367824T1 (de) | Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b | |
DE50000676D1 (de) | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis | |
ATE253945T1 (de) | Verwendung von wundverbänden zur behandlung von akuten wunden | |
DE60213968D1 (de) | Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen |